MedTrace Logo

Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT

NCT00566462 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2018-09-06

Study results available
· View outcomes & findings →

Summary

This is a two-arm, double-blind, placebo-controlled study.

Conditions

Interventions

DRUG

perampanel

2 mg/d for 14 days followed by 4 mg/d for 14 days

DRUG

placebo

Matching placebo for for 14 days followed by 4 mg/d for 14 days

Sponsors & Collaborators

  • Eisai Inc.

    lead INDUSTRY

Principal Investigators

  • Patricia Cole, PhD, MD · Eisai Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-12-01
Completion
2008-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00566462 on ClinicalTrials.gov